Profiling the host response to malaria vaccination and malaria challenge

Vaccine

Volumn 33, Issue 40, 2015, Pages 5316-5320

  Dunachie, Susanna ^a,b   Hill, Adrian V S ^a   Fletcher, Helen A ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Biomarkers; Immunity; Malaria; Microarray; Plasmodium falciparum; Transcript; Vaccine

Indexed keywords

MALARIA VACCINE; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; ANOPHELES STEPHENSI; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED CLINICAL TRIAL (TOPIC); GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; LIFE CYCLE STAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MALARIA CONTROL; NONHUMAN; OUTCOME ASSESSMENT; PARASITE IMMUNITY; PATTERN RECOGNITION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIMIAN VIRUS; SPOROZOITE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTOMICS; UPREGULATION; VACCINATION; ANIMAL; GENETICS; IMMUNITY; IMMUNOLOGY; MALARIA, FALCIPARUM; MICROARRAY ANALYSIS; PLASMODIUM;

ADAPTIVE IMMUNITY; ANIMALS; BIOMARKERS; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MICROARRAY ANALYSIS; PLASMODIUM; VACCINATION;

EID: 84941810075     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.107     Document Type: Article

References (68)

1. World Malaria Report 2014, World Health Organization, Geneva, Switzerland.
2. Ashley E.A., Dhorda M., Fairhurst R.M., Amaratunga C., Lim P., Suon S., et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014, 371:411-423.
3. Ranson H., N'Guessan R., Lines J., Moiroux N., Nkuni Z., Corbel V. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control. Trends Parasitol 2011, 27:91-98.
4. The RTSS Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014, 11:e1001685.
5. Wipasa J., Elliott S., Xu H., Good M.F. Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol 2002, 80:401-414.
6. Riley E.M., Stewart V.A. Immune mechanisms in malaria: new insights in vaccine development. Nat Med 2013, 19:168-178.
7. Richie T. High road, low road? Choices and challenges on the pathway to a malaria vaccine. Parasitology 2006, 133(Suppl):S113-S144.
8. Barry A.E., Arnott A. Strategies for designing and monitoring malaria vaccines targeting diverse antigens. Front Immunol 2014, 5:359.
9. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
10. Bull P.C., Lowe B.S., Kortok M., Molyneux C.S., Newbold C.I., Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998, 4:358-360.
11. Marsh K., Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006, 28:51-60.
12. Doolan D.L., Dobano C., Baird J.K. Acquired immunity to malaria. Clin Microbiol Rev 2009, 22:13-36.
13. Clyde D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975, 24:397-401.
14. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
15. The Rainbow Tables. Geneva, Switzerland: World Health Organization (accessed 18.03.15).
16. Ouattara A., Laurens M.B. Vaccines against malaria. Clin Infect Dis Off Publ Infect Dis Soc Am 2015, 60:930-936.
17. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012, 11:11.
18. Florens L., Washburn M.P., Raine J.D., Anthony R.M., Grainger M., Haynes J.D., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002, 419:520-526.
19. Wang R., Richie T.L., Baraceros M.F., Rahardjo N., Gay T., Banania J.G., et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 2005, 73:2863-2872.
20. Porter D.W., Thompson F.M., Berthoud T.K., Hutchings C.L., Andrews L., Biswas S., et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011, 29:7514-7522.
21. Regules J.A., Cummings J.F., Ockenhouse C.F. The RTS,S vaccine candidate for malaria. Expert Rev Vac 2011, 10:589-599.
22. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
23. Heppner D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005, 23:2243-2250.
24. Dunachie S.J., Walther M., Vuola J.M., Webster D.P., Keating S.M., Berthoud T., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 2006, 24:2850-2859.
25. Ockenhouse C.F., Regules J., Tosh D., Cowden J., Kathcart A., Cummings J., et al. Ad35.CS.01 - RTS. S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults. PLOS ONE 2015, 10:e0131571.
26. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9:729-735.
27. Ewer K.J., O'Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836.
28. Hodgson S.H., Ewer K.J., Bliss C.M., Edwards N.J., Rampling T., Anagnostou N.A., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 2015, 211:1076-1086.
29. Chuang I., Sedegah M., Cicatelli S., Spring M., Polhemus M., Tamminga C., et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLOS ONE 2013, 8:e55571.
30. Saul A. Mosquito stage, transmission blocking vaccines for malaria. Curr Opin Infect Dis 2007, 20:476-481.
31. Nikolaeva D., Draper S.J., Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vac 2015, 1-28.
32. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11:57-64.
33. Hodgson S.H., Douglas A.D., Edwards N.J., Kimani D., Elias S.C., Chang M., et al. Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malar J 2015, 14:33.
34. Chulay J.D., Schneider I., Cosgriff T.M., Hoffman S.L., Ballou W.R., Quakyi I.A., et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986, 35:66-68.
35. Roestenberg M., de Vlas S.J., Nieman A.E., Sauerwein R.W., Hermsen C.C. Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J Infect Dis 2012, 206:319-323.
36. Epstein J.E. Taking a bite out of malaria: controlled human malaria infection by needle and syringe. Am J Trop Med Hyg 2013, 88:3-4.
37. Chen Q., Fernandez V., Sundstrom A., Schlichtherle M., Datta S., Hagblom P., et al. Developmental selection of var gene expression in Plasmodium falciparum. Nature 1998, 394:392-395.
38. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
39. Ponnudurai T., Meuwissen J.H., Leeuwenberg A.D., Verhave J.P., Lensen A.H. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans R Soc Trop Med Hyg 1982, 76:242-250.
40. Bejon P., Andrews L., Andersen R.F., Dunachie S., Webster D., Walther M., et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005, 191:619-626.
41. White M.T., Bejon P., Olotu A., Griffin J.T., Bojang K., Lusingu J., et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med 2014, 12:117.
42. Aide P., Dobano C., Sacarlal J., Aponte J.J., Mandomando I., Guinovart C., et al. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 2011, 29:6059-6067.
43. Leroux-Roels G., Leroux-Roels I., Clement F., Ofori-Anyinam O., Lievens M., Jongert E., et al. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive adults. Hum Vac Immunother 2014, 10:2211-2219.
44. Olotu A., Moris P., Mwacharo J., Vekemans J., Kimani D., Janssens M., et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P. falciparum clinical malaria. PLoS ONE 2011, 6:e25786.
45. Ansong D., Asante K.P., Vekemans J., Owusu S.K., Owusu R., Brobby N.A., et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE 2011, 6:e18891.
46. Lumsden J.M., Schwenk R.J., Rein L.E., Moris P., Janssens M., Ofori-Anyinam O., et al. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-alpha producing effector and central memory CD4 T cells. PLoS ONE 2011, 6:e20775.
47. Agnandji S.T., Fendel R., Mestre M., Janssens M., Vekemans J., Held J., et al. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D). PLoS ONE 2011, 6:e18559.
48. Horowitz A., Hafalla J.C., King E., Lusingu J., Dekker D., Leach A., et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J Immunol 2012, 188:5054-5062.
49. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma. J Immunol 2003, 171:6961-6967.
50. White M.T., Bejon P., Olotu A., Griffin J.T., Riley E.M., Kester K.E., et al. The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLOS ONE 2013, 8:e61395.
51. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341:323-326.
52. Campo J.J., Aponte J.J., Skinner J., Nakajima R., Molina D.M., Liang L., et al. RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites. Mol Cell Proteomics: MCP 2015, 14:519-531.
53. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78:145-153.
54. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., Rollier C.S., et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011, 187:1347-1357.
55. Sedegah M., Hollingdale M.R., Farooq F., Ganeshan H., Belmonte M., Kim Y., et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLOS ONE 2014, 9:e106241.
56. Tse S.W., Cockburn I.A., Zhang H., Scott A.L., Zavala F. Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun 2013, 14:302-309.
57. Wirth T.C., Xue H.H., Rai D., Sabel J.T., Bair T., Harty J.T., et al. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity 2010, 33:128-140.
58. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
59. Vahey M.T., Wang Z., Kester K.E., Cummings J., Heppner D.G., Nau M.E., et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. J Infect Dis 2010, 201:580-589.
60. Li S., Rouphael N., Duraisingham S., Romero-Steiner S., Presnell S., Davis C., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat immunol 2014, 15:195-204.
61. Dunachie S., Berthoud T., Hill A.V., Fletcher H.A. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Vaccine 2015, 33:5321-5331.
62. Chaussabel D., Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol 2014, 14:271-280.
63. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
64. Koh G.C., Schreiber M.F., Bautista R., Maude R.R., Dunachie S., Limmathurotsakul D., et al. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. PLOS ONE 2013, 8:e54961.
65. Hoek K.L., Samir P., Howard L.M., Niu X., Prasad N., Galassie A., et al. A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination. PLOS ONE 2015, 10:e0118528.
66. Duale N., Lipkin W.I., Briese T., Aarem J., Ronningen K.S., Aas K.K., et al. Long-term storage of blood RNA collected in RNA stabilizing Tempus tubes in a large biobank - evaluation of RNA quality and stability. BMC Res Notes 2014, 7:633.
67. Tao H., Beineke P., Li B., Alberts W., Rosenberg S., Kvam E., et al. Evaluation of a solid matrix for collection and ambient storage of RNA from whole blood. BMC Clin Pathol 2014, 14:22.
68. Doolan D.L., Mu Y., Unal B., Sundaresh S., Hirst S., Valdez C., et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008, 8:4680-4694.